What is GMAB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 149.54B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GMAB?

P/E (TTM) is 28.48 and 52-week range is $1512.00 to $2603.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GMAB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GMAB?

The company profile lists revenue (TTM) near $4.17B, net income (TTM) near $796M, EPS (TTM) near $12.69 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Genmab A/S based, and what identifiers does Chartloom list?

The company context section lists headquarters in Valby, DK, 62.4M shares outstanding, ISIN DK0010272202 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Genmab A/S

$GMAB

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Employees

3,029

Website

www.genmab.com/

IPO

2000-10-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)